HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ying Chen Selected Research

Ephrin-B2 (Ephrin B2)

2/2022Downregulation of EphB2 by RNA interference attenuates glial/fibrotic scar formation and promotes axon growth.
1/2021EphB2 knockdown decreases the formation of astroglial-fibrotic scars to promote nerve regeneration after spinal cord injury in rats.
10/2017RNAi-mediated ephrin-B2 silencing attenuates astroglial-fibrotic scar formation and improves spinal cord axon growth.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ying Chen Research Topics

Disease

461Neoplasms (Cancer)
11/2022 - 09/2002
137Inflammation (Inflammations)
12/2022 - 01/2000
74Infections
07/2022 - 06/2002
67Neoplasm Metastasis (Metastasis)
02/2022 - 07/2004
61Lung Neoplasms (Lung Cancer)
12/2022 - 10/2009
55Carcinogenesis
01/2022 - 01/2002
53Breast Neoplasms (Breast Cancer)
04/2022 - 12/2008
49Fibrosis (Cirrhosis)
06/2022 - 03/2005
45Stomach Neoplasms (Stomach Cancer)
07/2022 - 01/2003
41Ovarian Neoplasms (Ovarian Cancer)
01/2022 - 03/2004
37Hypoxia (Hypoxemia)
01/2022 - 05/2003
35Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
06/2022 - 02/2011
35Hepatocellular Carcinoma (Hepatoma)
04/2022 - 03/2005
32Parkinson Disease (Parkinson's Disease)
06/2022 - 04/2002
31COVID-19
12/2022 - 01/2020
31Alzheimer Disease (Alzheimer's Disease)
11/2022 - 02/2007
30Insulin Resistance
06/2022 - 08/2009
30Carcinoma (Carcinomatosis)
02/2022 - 01/2003
28Wounds and Injuries (Trauma)
08/2022 - 05/2006
26Pneumonia (Pneumonitis)
11/2022 - 10/2009
25Pancreatic Neoplasms (Pancreatic Cancer)
08/2021 - 07/2005
24Prostatic Neoplasms (Prostate Cancer)
12/2021 - 12/2008
23Colorectal Neoplasms (Colorectal Cancer)
02/2022 - 07/2005
23Type 2 Diabetes Mellitus (MODY)
11/2021 - 12/2008
23Atherosclerosis
09/2021 - 12/2008
22Sepsis (Septicemia)
07/2022 - 02/2002
22Silicosis
01/2020 - 02/2004
21Adenocarcinoma
01/2022 - 12/2009
20Adenocarcinoma of Lung
06/2022 - 08/2010
19Obesity
01/2022 - 12/2007
19Lymphatic Metastasis
07/2021 - 01/2003
18Neuroinflammatory Diseases
05/2022 - 01/2014
18Body Weight (Weight, Body)
01/2021 - 12/2004
17Glioma (Gliomas)
04/2022 - 03/2011
17Ischemia
01/2022 - 05/2009
16Rheumatoid Arthritis
12/2022 - 09/2003
16Hemorrhage
04/2022 - 04/2005
16Hypertension (High Blood Pressure)
01/2022 - 11/2005
16Pancreatitis
07/2021 - 01/2012
16Necrosis
05/2021 - 07/2006
16Cardiovascular Diseases (Cardiovascular Disease)
01/2021 - 03/2011
15Pain (Aches)
11/2022 - 06/2008
15Stroke (Strokes)
04/2022 - 12/2006
15Heart Failure
07/2021 - 04/2004
15Mitochondrial Diseases (Mitochondrial Disease)
06/2021 - 06/2008
14Neurodegenerative Diseases (Neurodegenerative Disease)
09/2022 - 11/2006
14Multiple Myeloma
01/2022 - 10/2005
14Glioblastoma (Glioblastoma Multiforme)
01/2022 - 09/2013
14Autoimmune Diseases (Autoimmune Disease)
11/2019 - 02/2004
14Schizophrenia (Dementia Praecox)
01/2019 - 07/2002
13Melanoma (Melanoma, Malignant)
01/2022 - 07/2003
13Uterine Cervical Neoplasms (Cancer of the Cervix)
01/2022 - 01/2013
13Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2022 - 02/2007

Drug/Important Bio-Agent (IBA)

193Proteins (Proteins, Gene)FDA Link
11/2022 - 07/2002
95Pharmaceutical PreparationsIBA
11/2022 - 01/2002
93Biomarkers (Surrogate Marker)IBA
12/2022 - 09/2006
62Biological ProductsIBA
07/2022 - 01/2003
57Messenger RNA (mRNA)IBA
07/2022 - 07/2002
55CytokinesIBA
03/2022 - 09/2003
54MicroRNAs (MicroRNA)IBA
01/2022 - 01/2011
44Glucose (Dextrose)FDA LinkGeneric
07/2022 - 01/2005
36Small Interfering RNA (siRNA)IBA
11/2022 - 02/2007
36Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
05/2022 - 01/2003
35LipidsIBA
07/2022 - 02/2009
33AntigensIBA
11/2022 - 07/2004
33EnzymesIBA
01/2022 - 02/2002
31Therapeutic UsesIBA
07/2022 - 02/2004
31Silicon Dioxide (Silica)FDA LinkGeneric
04/2021 - 05/2009
29Cisplatin (Platino)FDA LinkGeneric
02/2022 - 09/2006
28DNA (Deoxyribonucleic Acid)IBA
12/2019 - 06/2005
26RNA (Ribonucleic Acid)IBA
11/2022 - 05/2011
23Long Noncoding RNAIBA
05/2022 - 06/2015
22Peptides (Polypeptides)IBA
08/2022 - 02/2007
22Oxygen (Dioxygen)IBA
01/2022 - 08/2009
21Interleukin-6 (Interleukin 6)IBA
01/2022 - 04/2011
20Retinaldehyde (Retinal)IBA
10/2021 - 06/2008
19Uric Acid (Urate)IBA
07/2022 - 06/2012
19CateninsIBA
03/2022 - 11/2012
17AntioxidantsIBA
08/2022 - 05/2007
17Reactive Oxygen Species (Oxygen Radicals)IBA
03/2022 - 01/2017
17Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2022 - 09/2003
16Neuroprotective AgentsIBA
06/2022 - 01/2013
16CholesterolIBA
01/2022 - 10/2005
16LigandsIBA
12/2021 - 12/2008
15CollagenIBA
03/2022 - 01/2009
15Phosphotransferases (Kinase)IBA
01/2022 - 11/2009
15Antiviral Agents (Antivirals)IBA
10/2021 - 06/2002
15CalciumIBA
01/2020 - 01/2008
14Indicators and Reagents (Reagents)IBA
06/2022 - 09/2002
14ErbB Receptors (EGF Receptor)IBA
02/2022 - 06/2010
13VaccinesIBA
12/2022 - 01/2011
13Transcription Factors (Transcription Factor)IBA
01/2022 - 07/2006
13Amyloid (Amyloid Fibrils)IBA
11/2021 - 10/2008

Therapy/Procedure

203Therapeutics
12/2022 - 07/2003
85Drug Therapy (Chemotherapy)
11/2022 - 08/2010
31Radiotherapy
01/2022 - 01/2012
23Immunotherapy
06/2022 - 01/2017
16Aftercare (After-Treatment)
05/2022 - 12/2009
14Ligation
01/2022 - 11/2005
13Chinese Traditional Medicine (Traditional Chinese Medicine)
06/2022 - 12/2014